Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression

Mutations in the KEAP1-NRF2 pathway occur in up to a third of non-small cell lung cancer (NSCLC) cases and often confer resistance to therapy and poor outcomes. Here, we developed murine alleles of the KEAP1 and NRF2 mutations found in human NSCLC and comprehensively interrogated their impact on tumor initiation and progression. Chronic Nrf2 stabilization by Keap1 or Nrf2 mutation was not sufficient to induce tumorigenesis, even in the absence of tumor suppressors p53 or Lkb1. When combined with KrasG12D/+, constitutive Nrf2 activation promoted lung tumor initiation and early progression of hyperplasia to low-grade tumors but impaired their progression to advanced-grade tumors, which was reversed by Nrf2 deletion. Finally, NRF2 overexpression in KEAP1 mutant NSCLC cell lines was detrimental to cell proliferation, viability, and anchorage-independent colony formation. Collectively, our results establish the context-dependence and activity threshold for NRF2 during the lung tumorigenic process. Significance This study reports murine lung cancer models harboring mutations in the Keap1/Nrf2 pathway and highlights the context-dependent and diverse roles of Nrf2 during lung tumor initiation and progression.

[1]  N. Bardeesy,et al.  NRF2 activation induces NADH-reductive stress providing a metabolic vulnerability in lung cancer , 2022, bioRxiv.

[2]  J. Simon,et al.  TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice , 2022, Oncogene.

[3]  M. Pagano,et al.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion , 2021, Cell.

[4]  Donna D. Zhang,et al.  The Intricacies of NRF2 Regulation in Cancer. , 2021, Seminars in cancer biology.

[5]  Christopher D. McFarland,et al.  A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. , 2021, Cancer discovery.

[6]  R. Zhuang,et al.  Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer , 2020, Frontiers in Oncology.

[7]  F. Gnad,et al.  NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes , 2020, Clinical Cancer Research.

[8]  G. DeNicola,et al.  Dissecting the Crosstalk between NRF2 Signaling and Metabolic Processes in Cancer , 2020, Cancers.

[9]  Masayuki Yamamoto,et al.  Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors , 2020, Cancer Research.

[10]  T. Wen,et al.  NRF2, a Transcription Factor for Stress Response and Beyond , 2020, International journal of molecular sciences.

[11]  Francisco J. Sánchez-Rivera,et al.  Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1 , 2020, Nature Cancer.

[12]  D. Petrov,et al.  Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo , 2020, bioRxiv.

[13]  Yong Zhang,et al.  Emerging substrate proteins of Kelch-like ECH associated protein 1 (Keap1) and potential challenges for the development of small-molecule inhibitors of the Keap1-nuclear factor erythroid 2-related factor 2 (Nrf2) protein-protein interaction. , 2020, Journal of medicinal chemistry.

[14]  R. Moellering,et al.  Photoproximity Profiling of Protein-Protein Interactions in Cells , 2019, bioRxiv.

[15]  Matthew E. Ritchie,et al.  Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma , 2019, Nature Communications.

[16]  B. Ueberheide,et al.  Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1 , 2019, Cell.

[17]  S. Eriksson,et al.  TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy , 2019, Proceedings of the National Academy of Sciences.

[18]  L. Saso,et al.  Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs , 2019, International journal of molecular sciences.

[19]  J. Asara,et al.  Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer , 2018, bioRxiv.

[20]  Matthew E. Ritchie,et al.  Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. , 2018, Cell metabolism.

[21]  H. Motohashi,et al.  NRF2 addiction in cancer cells , 2018, Cancer science.

[22]  Christopher D. McFarland,et al.  Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice , 2018, Nature Genetics.

[23]  P. Huppke,et al.  Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder , 2017, Nature Communications.

[24]  M. V. Vander Heiden,et al.  Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer , 2017, eLife.

[25]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[26]  Ash A. Alizadeh,et al.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. , 2017, Cancer discovery.

[27]  Christopher D. McFarland,et al.  A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo , 2017, Nature Methods.

[28]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[29]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[30]  J. Cook,et al.  Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate* , 2016, The Journal of Biological Chemistry.

[31]  Angela N. Brooks,et al.  High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.

[32]  T. Shibata,et al.  NRF2 Intensifies Host Defense Systems to Prevent Lung Carcinogenesis, but After Tumor Initiation Accelerates Malignant Cell Growth. , 2016, Cancer research.

[33]  R. Deberardinis,et al.  NRF2 regulates serine biosynthesis in non-small cell lung cancer , 2015, Nature Genetics.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[35]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[36]  M. Sporn,et al.  NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.

[37]  H. Aburatani,et al.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. , 2012, Cancer cell.

[38]  Michelle F Clasquin,et al.  LC-MS data processing with MAVEN: a metabolomic analysis and visualization engine. , 2012, Current protocols in bioinformatics.

[39]  B. Sobhian,et al.  PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function , 2012, Molecular and Cellular Biology.

[40]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[41]  S. Biswal,et al.  Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. , 2010, Antioxidants & redox signaling.

[42]  V. Raman,et al.  Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. , 2010, Carcinogenesis.

[43]  Stephen G Swisher,et al.  Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.

[44]  Takafumi Suzuki,et al.  Genetic Analysis of Cytoprotective Functions Supported by Graded Expression of Keap1 , 2010, Molecular and Cellular Biology.

[45]  N. Yoo,et al.  Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin , 2010, The Journal of pathology.

[46]  Hailong Wu,et al.  Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth , 2010, Molecular Cancer Therapeutics.

[47]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[48]  Tsutomu Ohta,et al.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.

[49]  Rui Wang,et al.  Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. , 2008, Biochemical and biophysical research communications.

[50]  M. Hannink,et al.  PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. , 2008, Experimental cell research.

[51]  S. Yokoyama,et al.  Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response , 2007, Molecular and Cellular Biology.

[52]  J. Herman,et al.  Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer , 2006, PLoS medicine.

[53]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[54]  H. Akaza,et al.  Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis , 2004, Cancer Research.

[55]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[56]  J. D. Engel,et al.  Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation , 2003, Nature Genetics.

[57]  K. Itoh,et al.  Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. , 2003, Carcinogenesis.

[58]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[59]  K. Itoh,et al.  Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. , 2001, Toxicology and applied pharmacology.

[60]  M. Kwak,et al.  Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Bridgid E Hast,et al.  Molecular and Cellular Pathobiology Cancer-derived Mutations in Keap1 Impair Nrf2 Degradation but Not Ubiquitination , 2022 .

[62]  T. Kensler,et al.  Nrf2: friend or foe for chemoprevention? , 2010, Carcinogenesis.

[63]  J. D. Engel,et al.  Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. , 1999, Genes & development.